ABEO
Price
$5.19
Change
+$0.10 (+1.96%)
Updated
Jan 14 closing price
Capitalization
280.98M
67 days until earnings call
Intraday BUY SELL Signals
CRIS
Price
$0.90
Change
-$0.00 (-0.00%)
Updated
Jan 14 closing price
Capitalization
11.69M
Intraday BUY SELL Signals
Interact to see
Advertisement

ABEO vs CRIS

Header iconABEO vs CRIS Comparison
Open Charts ABEO vs CRISBanner chart's image
Abeona Therapeutics
Price$5.19
Change+$0.10 (+1.96%)
Volume$721.42K
Capitalization280.98M
Curis
Price$0.90
Change-$0.00 (-0.00%)
Volume$664.75K
Capitalization11.69M
ABEO vs CRIS Comparison Chart in %
ABEO
Daily Signal:
Gain/Loss:
CRIS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ABEO vs. CRIS commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABEO is a Hold and CRIS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (ABEO: $5.19 vs. CRIS: $0.90)
Brand notoriety: ABEO and CRIS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABEO: 42% vs. CRIS: 120%
Market capitalization -- ABEO: $280.98M vs. CRIS: $11.69M
ABEO [@Biotechnology] is valued at $280.98M. CRIS’s [@Biotechnology] market capitalization is $11.69M. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABEO’s FA Score shows that 1 FA rating(s) are green whileCRIS’s FA Score has 0 green FA rating(s).

  • ABEO’s FA Score: 1 green, 4 red.
  • CRIS’s FA Score: 0 green, 5 red.
According to our system of comparison, ABEO is a better buy in the long-term than CRIS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABEO’s TA Score shows that 5 TA indicator(s) are bullish while CRIS’s TA Score has 4 bullish TA indicator(s).

  • ABEO’s TA Score: 5 bullish, 3 bearish.
  • CRIS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ABEO is a better buy in the short-term than CRIS.

Price Growth

ABEO (@Biotechnology) experienced а -0.57% price change this week, while CRIS (@Biotechnology) price change was +7.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.47%. For the same industry, the average monthly price growth was +3.44%, and the average quarterly price growth was +44.89%.

Reported Earning Dates

ABEO is expected to report earnings on Mar 23, 2026.

Industries' Descriptions

@Biotechnology (+0.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABEO($281M) has a higher market cap than CRIS($11.7M). ABEO YTD gains are higher at: -1.518 vs. CRIS (-8.368). ABEO has higher annual earnings (EBITDA): 89.8M vs. CRIS (-32.41M). ABEO has more cash in the bank: 207M vs. CRIS (9.05M). CRIS has less debt than ABEO: CRIS (1.97M) vs ABEO (24.1M). CRIS has higher revenues than ABEO: CRIS (11.6M) vs ABEO (400K).
ABEOCRISABEO / CRIS
Capitalization281M11.7M2,402%
EBITDA89.8M-32.41M-277%
Gain YTD-1.518-8.36818%
P/E Ratio4.29N/A-
Revenue400K11.6M3%
Total Cash207M9.05M2,287%
Total Debt24.1M1.97M1,225%
FUNDAMENTALS RATINGS
ABEO vs CRIS: Fundamental Ratings
ABEO
CRIS
OUTLOOK RATING
1..100
671
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
52
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
15100
PRICE GROWTH RATING
1..100
7792
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRIS's Valuation (52) in the Biotechnology industry is in the same range as ABEO (75) in the Pharmaceuticals Generic industry. This means that CRIS’s stock grew similarly to ABEO’s over the last 12 months.

CRIS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ABEO (100) in the Pharmaceuticals Generic industry. This means that CRIS’s stock grew similarly to ABEO’s over the last 12 months.

ABEO's SMR Rating (15) in the Pharmaceuticals Generic industry is significantly better than the same rating for CRIS (100) in the Biotechnology industry. This means that ABEO’s stock grew significantly faster than CRIS’s over the last 12 months.

ABEO's Price Growth Rating (77) in the Pharmaceuticals Generic industry is in the same range as CRIS (92) in the Biotechnology industry. This means that ABEO’s stock grew similarly to CRIS’s over the last 12 months.

ABEO's P/E Growth Rating (98) in the Pharmaceuticals Generic industry is in the same range as CRIS (100) in the Biotechnology industry. This means that ABEO’s stock grew similarly to CRIS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABEOCRIS
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 13 days ago
81%
Bullish Trend 20 days ago
74%
Declines
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 13 days ago
90%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ABEO
Daily Signal:
Gain/Loss:
CRIS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MOLN4.210.08
+1.94%
Molecular Partners AG
GDYN9.400.16
+1.73%
Grid Dynamics Holdings
HBAN17.680.18
+1.03%
Huntington Bancshares
NAMS31.920.06
+0.19%
NewAmsterdam Pharma Company NV
PTLE0.11N/A
-3.12%
PTL Ltd

ABEO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABEO has been loosely correlated with OCUL. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ABEO jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABEO
1D Price
Change %
ABEO100%
+1.96%
OCUL - ABEO
44%
Loosely correlated
+6.14%
RGNX - ABEO
43%
Loosely correlated
-0.66%
AURA - ABEO
43%
Loosely correlated
+3.95%
SLDB - ABEO
42%
Loosely correlated
+12.60%
KALV - ABEO
41%
Loosely correlated
+2.01%
More

CRIS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRIS has been loosely correlated with ORMP. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if CRIS jumps, then ORMP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRIS
1D Price
Change %
CRIS100%
+0.90%
ORMP - CRIS
34%
Loosely correlated
+7.37%
VTGN - CRIS
33%
Loosely correlated
+2.32%
ABEO - CRIS
33%
Poorly correlated
+1.96%
CGON - CRIS
33%
Poorly correlated
+5.57%
ALGS - CRIS
32%
Poorly correlated
-2.06%
More